Close Menu

NEW YORK (GenomeWeb) – Catalyst Pharmaceuticals has signed an agreement to use Biocept's Target Selector liquid biopsy platform to screen for cancer in patients enrolled in a clinical trial of its rare disease drug Firdapse (amifampridine phosphate).

Firdapse is currently approved in the EU to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease often associated with malignancies such as small cell lung cancer. Catalyst holds the drug's North American rights.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.